STOCK MARKETS

+48%, +31%, +24%: Which AI-picked stocks are climbing while tech wobbles?

By Investing.com4 min readInvesting.com
+48%, +31%, +24%: Which AI-picked stocks are climbing while tech wobbles?

Investing.com – Wall Street’s pullback deepened on Tuesday. The S&P 500 fell 1.0% to 7,340.89 and the Dow Jones Industrial Average lost 1.6%, leaving the S&P 500 about 2.9% below last Friday’s close as investors questioned how much to pay for AI and chip stocks. Nvidia reported after the closing bell. Away from the tech trade, Investing.com’s ProPicks AI is holding three stocks that are up 24% to 48% since our models added them.

Want to see the full list? InvestingPro members can access November’s complete set of AI-powered stock picks (and their rationales) HERE – Now available at 55% off as part of our Black Friday Early Bird Sale

Three stocks from three corners of healthcare

Healthcare Heroes, our AI strategy for the sector, holds all three. Each name was added at the closing price on the first day of the month shown.

Tenet Healthcare (NYSE:THC) – up 48.2% since entry. Our AI added the hospital and surgery-center operator on April 1 at $190.27, and it closed Tuesday at $282.07, up 3.2% so far in November. Tenet reported third-quarter results on Oct. 29. Revenue rose to $5.63 billion from $5.29 billion, and adjusted EPS reached $6.64 against $3.70 a year earlier. Adjusted EBITDA climbed 23.3% to $1.36 billion. The quarter included a one-time benefit from a contract termination and revenue-cycle timing, which Tenet put at about $147 million of net favorable impact on adjusted EBITDA. It raised its full-year adjusted EBITDA outlook to $5.05–$5.20 billion, a $195 million increase at the midpoint, and lifted its adjusted EPS range to $22.05–$23.01.

Gilead Sciences (NASDAQ:GILD) – up 30.9% since entry. Healthcare Heroes added the biopharma on May 1 at $130.06, and it closed Tuesday at $170.26. Gilead reported on Oct. 29. Product sales rose 13% to $8.3 billion, led by HIV, where sales climbed 18% to $6.2 billion. Biktarvy grew 10% to $4.1 billion and Descovy grew 49% to $1.0 billion, and Trodelvy rose 42% to $506 million. Non-GAAP EPS was $2.55 against $2.47 a year earlier. The company raised its 2026 product-sales outlook to $31.0–$31.3 billion from $30.1–$30.4 billion. The shares are little changed this month.

Mettler-Toledo (NYSE:MTD) – up 24.5% since entry. Our AI added the lab-instrument maker on Sept. 1 at $1,375.96, and it closed Tuesday at $1,712.95, up 2.3% this month. Mettler reported on Nov. 5. Sales rose 6% to about $1.09 billion, and adjusted EPS grew 13% to $12.57 from $11.15. Sales in Asia and the rest of the world rose 16%. It raised its 2026 adjusted EPS guidance to $47.70–$47.90 from $47.15–$47.50 and issued a first look at 2027, with adjusted EPS of $52.50–$53.50.

Where the book stands

Healthcare Heroes is up 28.9% for 2026, 7.0 percentage points ahead of the S&P 500 Health Care index, and up 63.9% since launch, 19.8 points ahead of that benchmark. In November it is up 1.0% while the S&P 500 is down about 3.2% over the same stretch. Each strategy holds up to 20 stocks at equal weight and re-ranks monthly, so no single stock or sector can dominate the way a mega-cap can in a cap-weighted index. Equal weighting also caps the upside of any one winner.

Still not a member? Then here’s your chance to get the full list NOW:

  • App users can subscribe here
  • Web users can subscribe here

How Investing.com’s AI-Powered Stock Picker Works

At the beginning of each month, our proprietary AI system evaluates thousands of global equities using a complex blend of historical data, valuation signals, and forward-looking growth metrics.

By processing more than 15 years of financial data across more than 150 quantitative models, the engine identifies up to 20 high-conviction stocks per strategy based on their projected medium-term upside potential.

Every month, these strategies undergo a strict rebalancing process. New opportunities are added, strong performers are retained, and stocks that no longer meet the criteria are removed.

To consistently track performance, each strategy utilises equal weighting across all selected stocks. While investors are free to adjust their own allocations, this structure provides a transparent benchmark for evaluating overall model performance.

The goal is to keep capital positioned in the companies showing the strongest combination of momentum, valuation, and business performance.

*Live performance is recorded since our official launch of the Beat the S&P 500 strategy in October 2023.

Subscription prices mentioned in articles are accurate at the time of publication. We regularly test different offers for our members, which may vary by region.

Past performance does not guarantee future results. Prices are accurate at the time of publication and may vary by region.